Miniatura

Fitxers

watz2017_2685.pdf (2.38 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2017-08-24

Llicència de publicació

cc by-nc (c) Watz et al., 2017
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/116223

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.2147/COPD.S143488

Resum

The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 mug twice daily on lung hyperinflation, exercise capacity, and physical activity in patients with moderate-to-severe COPD. Patients received AB/FF (n=134) or placebo (n=133) (1:1) via the Genuair/Pressair(R) dry powder inhaler for 8 weeks. From Weeks 5 to 8, all patients participated in behavioral intervention (BI; daily messages providing step goals). The primary end point was trough functional residual capacity (FRC) at Week 4. Exercise endurance time and physical activity were assessed at Week 4 (pharmacotherapy only) and at Week 8 (8 weeks of pharmacotherapy plus 4 weeks of BI). Other end points included post-dose FRC, residual volume, and inspiratory capacity (IC) at rest and during exercise. After 4 weeks, trough FRC improved with AB/FF versus placebo but did not reach significance (125 mL; P=0.0690). However, post-dose FRC, residual volume, and IC at rest improved significantly with AB/FF at Week 4 versus placebo (all P<0.0001). AB/FF significantly improved exercise endurance time and IC at isotime versus placebo at Week 4 (P<0.01 and P<0.0001, respectively) and Week 8 (P<0.05 and P<0.0001, respectively). AB/FF achieved higher step counts (P<0.01) with fewer inactive patients (P<0.0001) at Week 4 versus placebo. Following BI, AB/FF maintained improvements in physical activity at Week 8 and nonsignificant improvements were observed with placebo. AB/FF 400/12 mug demonstrated improvements in lung hyperinflation, exercise capacity, and physical activity versus placebo that were maintained following the addition of BI. A 4-week period of BI might be too short to augment the improvements of physical activity observed with AB/FF.

Matèries

Malalties pulmonars obstructives cròniques, Condició física

Matèries (anglès)

Chronic obstructive pulmonary diseases, Physical fitness

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

WATZ, Henrik, TROOSTERS, Thierry, BEEH, Kai m., GARCÍA AYMERICH, Judith, PAGGIARO, Pierluigi, MOLINS, Eduard, NOTARI, Massimo, ZAPATA, Antonio, JARRETA, Diana, GARCIA GIL, Esther. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation,
                exercise capacity, and physical activity in patients with COPD. _International Journal of Chronic Obstructive Pulmonary Disease_. 2017. Vol. 12, pàgs. 2545-2558. [consulta: 21 de gener de 2026]. ISSN: 1176-9106. [Disponible a: https://hdl.handle.net/2445/116223]

Exportar metadades

JSON - METS

Compartir registre